Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Advaxis, Inc. (NASDAQ: ADXS).

Full DD Report for ADXS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADXS)

Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advaxis, Inc. (NASDAQ:ADXS), e.l.f. Beauty Inc. (NYSE:ELF), Heron Therapeu...
Source: GlobeNewswire
Date: May, 14 2018 08:10
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of their Lm vector that presents ...
Source: Business Wire
Date: May, 11 2018 08:00
NEW YORK, NY, April 25, 2018 (GLOBE NEWSWIRE) - Metrospaces, Inc. (MSPC) announces another record revenue month in March 2018 for Etelix.
Mr. Silva stated: “Our fundamentals continue to be very strong, our growth continues strong and Etelix management continues to hit record revenue numbers.  Management’s budget revenue for April 2018 was $778,906; however, the company did 7% higher revenue than our forecast, ...
Source: Stock Market Press
Date: April, 25 2018 09:22
New leadership at Advaxis
Advaxis ( ADXS -1.2% ) appoints Ken Berlin as President & CEO effective today replacing interim CEO Anthony Lombardo. He joins the firm from Rosetta Genomics were he was also President & CEO. More news on: Advaxis Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 23 2018 12:00
Advaxis Announces Executive Leadership Changes
Kenneth A. Berlin appointed President, CEO and Director; Dr. Andres A. Gutierrez named Chief Medical Officer; Sara Bonstein, CFO, to depart Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunothera...
Source: Business Wire
Date: April, 23 2018 08:00
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
Lm platform targets common mutations in tumor driver genes   Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT preclinical data...
Source: Business Wire
Date: April, 17 2018 08:00
Data Highlighting Advaxis' ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has accepted the abstract titled “ADXS-PSA plus pembrolizumab (pembro...
Source: Business Wire
Date: April, 02 2018 08:00
Wired News - Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam
Stock Monitor: Advaxis Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on Recro Pharma, Inc. (NASDAQ: REPH ). If you want access to this report all you need to do is sign up now by clicking the following...
Source: ACCESSWIRE IA
Date: March, 29 2018 07:00
Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
Including Three Late-Breaking Poster Presentations Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its Lm ...
Source: Business Wire
Date: March, 26 2018 08:00
The No BS Plan Report, Week 6: Are We Now Seeing Some Inflection?
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Hello all! Welcome to another week of the No BS Plan report. And this week we're in the m...
Source: SeekingAlpha
Date: March, 24 2018 17:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-171.861.771.941.77694,162
2017-01-308.958.759.038.60385,424
2017-01-278.809.059.078.66463,796
2017-01-268.678.779.108.55710,512
2017-01-258.578.728.808.43617,671

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1727,22453,28751.0894Short
2018-08-1620,03151,64538.7859Short
2018-08-1534,24463,06054.3038Short
2018-08-1451,21378,36965.3485Short
2018-08-1351,01084,81860.1405Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADXS.


About Advaxis, Inc. (NASDAQ: ADXS)

Logo for Advaxis, Inc. (NASDAQ: ADXS)

Advaxis is a clinical stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio engineered to secrete an antigen/adjuvant fusion protein s that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS HPV is currently being evaluated in four clinical trials for human papillomavirus HPV associated cancers: recurrent/refractory cervical cancer India , locally advanced cervical cancer GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT , head amp neck cancer CRUK study, Clinical Trials.gov Identifier NCT , and anal cancer BrUOG study, Clinical Trials.gov Identifier NCT . Advaxis has over distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

 

Contact Information

 

 

Current Management

  • Thomas Moore / CEO
  • Daniel O Connor / EVP
  • Mark Rosenblum / Senior VP, CFO, Secretary
  • Robert Petit / Chief Scientific Officer
  • Thomas Moore / Chairman
  • Ronie A. Appel /
  • Richard Berman /
  • Thomas McKearn /
  • James Patton /
  • David Sidransky /

Current Share Structure

  • Market Cap: $98,350,036 - 05/14/2018
  • Authorized: 25,000,000 - 07/15/2013
  • Issue and Outstanding: 52,313,849 - 03/08/2018

 


Recent Filings from (NASDAQ: ADXS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018

 

 


Daily Technical Chart for (NASDAQ: ADXS)

Daily Technical Chart for (NASDAQ: ADXS)


Stay tuned for daily updates and more on (NASDAQ: ADXS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADXS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADXS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ADXS and does not buy, sell, or trade any shares of ADXS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/